• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The new long-acting coronary artery dilator molsidomine and its metabolite SIN-1.

作者信息

Sobolski J, Vandermoten P, Stoupel E, Berkenboom G, Degre S

出版信息

Am Heart J. 1985 Mar;109(3 Pt 2):700-3. doi: 10.1016/0002-8703(85)90686-6.

DOI:10.1016/0002-8703(85)90686-6
PMID:3838407
Abstract

We studied the effects of intracoronary injections of SIN-1 (0.8 mg), the active metabolite of molsidomine, on coronary artery diameters and coronary stenoses. In nine patients with abnormal angiograms measurements were made 4 and 8 minutes after SIN-1 administration. There was a statistically significant increase in coronary luminal diameter in proximal, medial, and distal segments as well as at the level of the stenoses. At 4 minutes after administration distal segments showed a mean increase in diameter of 50%, compared to a mean increase of 26% in proximal segments. In six patients with normal angiograms SIN-1 abolished three of four coronary spasms induced by ergonovine maleate. A protective effect of SIN-1 against the vasoconstrictor effects of ergonovine was still present at 8 minutes after administration. Heart rate and blood pressure remained unchanged throughout the study. We conclude that the vasodilation induced by SIN-1 in normal and stenotic coronary arteries is probably an important contribution to the antianginal efficacy of molsidomine and suggests that molsidomine may be effective in the prophylaxis of variant angina.

摘要

相似文献

1
The new long-acting coronary artery dilator molsidomine and its metabolite SIN-1.
Am Heart J. 1985 Mar;109(3 Pt 2):700-3. doi: 10.1016/0002-8703(85)90686-6.
2
Active and passive changes in coronary diameter after vasodilation with SIN-1, the active metabolite of molsidomine.用吗多明的活性代谢物SIN-1进行血管舒张后冠状动脉直径的主动和被动变化。
Am Heart J. 1985 Mar;109(3 Pt 2):694-9. doi: 10.1016/0002-8703(85)90685-4.
3
[Diameter changes of epicardial coronary arteries and coronary stenoses after intracoronary application of SIN 1, a molsidomine metabolite].[应用硝普钠代谢物SIN 1冠脉内给药后心外膜冠状动脉直径变化及冠状动脉狭窄情况]
Z Kardiol. 1983 Jul;72(7):404-9.
4
Prevention with molsidomine of coronary artery spasm caused by alkalosis.用吗多明预防碱中毒引起的冠状动脉痉挛。
Am Heart J. 1985 Mar;109(3 Pt 2):704-7.
5
Long-acting coronary vasodilatory action of the molsidomine metabolite Sin 1: a quantitative angiographic study.
Eur Heart J. 1987 Mar;8(3):263-70. doi: 10.1093/oxfordjournals.eurheartj.a062268.
6
Clinical and hemodynamic effects of the new dilator drug molsidomine.
Am Heart J. 1985 Mar;109(3 Pt 2):674-7. doi: 10.1016/0002-8703(85)90679-9.
7
Nitroglycerin-resistant coronary spasm treated with intracoronary linsidomine chlorhydrate (SIN-1).用冠状动脉内注射盐酸林西多明(SIN-1)治疗对硝酸甘油耐药的冠状动脉痉挛。
Eur Heart J. 1990 May;11(5):472-5. doi: 10.1093/oxfordjournals.eurheartj.a059731.
8
Mechanism of vasodilation by molsidomine.莫西多明的血管舒张机制。
Am Heart J. 1985 Mar;109(3 Pt 2):637-40. doi: 10.1016/0002-8703(85)90669-6.
9
[Pharmacological basis of therapy with molsidomine].[莫西多明治疗的药理学基础]
Herz. 1982 Oct;7(5):296-306.
10
[Molsidomine prevention of coronary artery spasm caused by alkalosis].[吗多明预防碱中毒所致冠状动脉痉挛]
Ann Cardiol Angeiol (Paris). 1983 Dec;32(8):545-9.

引用本文的文献

1
Nonresponsiveness to antianginal therapy--a frequent problem?
Cardiovasc Drugs Ther. 1988 May;2(1):71-7. doi: 10.1007/BF00054255.
2
Comparison of haemodynamic effects of nifedipine and molsidomine in patients with coronary artery disease.
Eur J Clin Pharmacol. 1989;37(5):443-7. doi: 10.1007/BF00558121.
3
Elimination of variable vasomotor tone in studies with repeated quantitative coronary angiography.在重复定量冠状动脉造影研究中消除可变的血管舒缩张力。
Int J Card Imaging. 1990;5(2-3):125-34. doi: 10.1007/BF01833981.